Based on the indirect clinical evidence that interleukin-6 (IL-6) is a key additional candidate mediator of ME, we interrogated the effect of IL-6 on blood–retinal barrier (BRB) integrity in vitro.

2017年10月1日 · There are two clinical trials investigating the blockage of IL-6 in DME patients. The first trial involves an IL-6 antibody (EBI-031; Eleven Biotherapeutics, Roche), a …

Therefore, research is being performed on the efficacy of anti-IL-6 treatment in DME. One clinical study evaluated the IL-6 humanized monoclonal antibody EBI-031 (Eleven Biotherapeutics, …

Dual inhibition of VEGF and IL-6 by KSI-501 confers superior normalization of cell morphology and junctional biology compared to either anti-VEGF or anti-IL-6 monotherapy in cell-based …

2002年7月1日 · We found that the levels of both IL-6 and VEGF were elevated in the vitreous fluid of subjects with hyperfluorescent DME. Our results suggest that IL-6 and VEGF may promote …

与传统酶联免疫吸附测定 (enzyme linked immunosorbent assay，ELISA)技术相比，新近出现的高通量检测技术，例如液相芯片，能同时测量少量房水或玻璃体液中的多种炎症因子，故而近年 …

This paper describes the current literature on the molecular pathophysiology of interleukin-6 (IL-6) in the genesis of macular edema and on the outcomes with IL-6 inhibitors in the treatment of …

In the present study, we found that the concentrations of both VEGF and IL-6 were significantly higher in the vitre-ous fluid of subjects with DME than in nondiabetic subjects and that …

This review summarizes the current knowledge of the biological processes providing an inflammatory basis for DR and DME. In addition, emerging therapeutic approaches targeting …

Peripheral blood IL-6 and IL-8 levels could play a role in the severity of DME and UME, respectively. IL-8 even seems to be independently associated with CMT and MV in UME …